Profile of tocilizumab and its potential in the treatment of giant cell arteritis
Susan Patricia Mollan,1,2 John Horsburgh,1 Bhaskar Dasgupta3 1Birmingham Neuro-Ophthalmology Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, 2Institute of Metabolism and Systems Research, University of Birmingham, 3Department of Rheumatology, Southen...
Main Authors: | Mollan SP, Horsburgh J, Dasgupta B |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-01-01
|
Series: | Eye and Brain |
Subjects: | |
Online Access: | https://www.dovepress.com/profile-of-tocilizumab-and-its-potential-in-the-treatment-of-giant-cel-peer-reviewed-article-EB |
Similar Items
-
EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01) -
Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
by: Maxime Samson, et al.
Published: (2021-01-01) -
Clinical aspects of the temporal arteritis
by: Palheta Neto, Francisco Xavier, et al.
Published: (2008-12-01) -
Giant cell arteritis: Genetic and epigenetic aspects
by: S V Guliaev, et al.
Published: (2017-08-01) -
Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study
by: Luca Quartuccio, et al.
Published: (2020-01-01)